The molecular diagnosis of the primary lesion revealed isocitrate dehydrogenase (IDH) wild type (IDH1R132 and IDH2R172), no mutation in the TERT promoter or BRAFV600E, no chromosome arm 1p/19q co-deletion, and a lack of MGMT promoter methylation, which suggests primary GBM with poor prognosis. This evidence concerns the gene MGMT and glioblastoma.